Dexmedetomidine as an adjuvant analgesic for intractable cancer pain

Seth B. Roberts, Colin P. Wozencraft, Patrick J. Coyne, Thomas J Smith

Research output: Contribution to journalArticle

Abstract

Dexmedetomidine (Precedex®) is an alpha-2 adrenergic agonist that can produce sedation and analgesia without causing respiratory depression. Its use has been described in patients undergoing mechanical ventilation, sedation for surgical and nonsurgical procedures, and prevention of withdrawal. We describe its use as an adjuvant analgesic in a patient with cancer pain refractory to multiple treatment modalities.

Original languageEnglish (US)
Pages (from-to)371-373
Number of pages3
JournalJournal of Palliative Medicine
Volume14
Issue number3
DOIs
StatePublished - Mar 1 2011
Externally publishedYes

Fingerprint

Dexmedetomidine
Intractable Pain
Analgesics
Adrenergic alpha-2 Receptor Agonists
Artificial Respiration
Respiratory Insufficiency
Analgesia
Cancer Pain
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Anesthesiology and Pain Medicine
  • Nursing(all)

Cite this

Dexmedetomidine as an adjuvant analgesic for intractable cancer pain. / Roberts, Seth B.; Wozencraft, Colin P.; Coyne, Patrick J.; Smith, Thomas J.

In: Journal of Palliative Medicine, Vol. 14, No. 3, 01.03.2011, p. 371-373.

Research output: Contribution to journalArticle

Roberts, Seth B. ; Wozencraft, Colin P. ; Coyne, Patrick J. ; Smith, Thomas J. / Dexmedetomidine as an adjuvant analgesic for intractable cancer pain. In: Journal of Palliative Medicine. 2011 ; Vol. 14, No. 3. pp. 371-373.
@article{68de03bf413c4cc7abe325940fa0610e,
title = "Dexmedetomidine as an adjuvant analgesic for intractable cancer pain",
abstract = "Dexmedetomidine (Precedex{\circledR}) is an alpha-2 adrenergic agonist that can produce sedation and analgesia without causing respiratory depression. Its use has been described in patients undergoing mechanical ventilation, sedation for surgical and nonsurgical procedures, and prevention of withdrawal. We describe its use as an adjuvant analgesic in a patient with cancer pain refractory to multiple treatment modalities.",
author = "Roberts, {Seth B.} and Wozencraft, {Colin P.} and Coyne, {Patrick J.} and Smith, {Thomas J}",
year = "2011",
month = "3",
day = "1",
doi = "10.1089/jpm.2010.0235",
language = "English (US)",
volume = "14",
pages = "371--373",
journal = "Journal of Palliative Medicine",
issn = "1096-6218",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Dexmedetomidine as an adjuvant analgesic for intractable cancer pain

AU - Roberts, Seth B.

AU - Wozencraft, Colin P.

AU - Coyne, Patrick J.

AU - Smith, Thomas J

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Dexmedetomidine (Precedex®) is an alpha-2 adrenergic agonist that can produce sedation and analgesia without causing respiratory depression. Its use has been described in patients undergoing mechanical ventilation, sedation for surgical and nonsurgical procedures, and prevention of withdrawal. We describe its use as an adjuvant analgesic in a patient with cancer pain refractory to multiple treatment modalities.

AB - Dexmedetomidine (Precedex®) is an alpha-2 adrenergic agonist that can produce sedation and analgesia without causing respiratory depression. Its use has been described in patients undergoing mechanical ventilation, sedation for surgical and nonsurgical procedures, and prevention of withdrawal. We describe its use as an adjuvant analgesic in a patient with cancer pain refractory to multiple treatment modalities.

UR - http://www.scopus.com/inward/record.url?scp=79952303264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952303264&partnerID=8YFLogxK

U2 - 10.1089/jpm.2010.0235

DO - 10.1089/jpm.2010.0235

M3 - Article

VL - 14

SP - 371

EP - 373

JO - Journal of Palliative Medicine

JF - Journal of Palliative Medicine

SN - 1096-6218

IS - 3

ER -